呼吸器内科

論文業績 2020 年 10 月～2021 年 9 月

原著
1. Machida K, Michael Aw, Brittany M. A. Salter, Xiaotian Ju, Manali Mukherjee, Gail M.
Gauvreau, Paul M. O’Byrne, Parameswaran Nair, Roma Sehmi. The Role of the TL1A/DR3 Axis in
the Activation of Group 2 Innate Lymphoid Cells in Subjects with Eosinophilic Asthma.

Am J Respir Crit Care Med. 2020 Oct 15; 202(8): 1105-1114.
2. Yoichiro Harada, Kazuki Nakajima, Takehiro Suzuki, Tomoko Fukushige, Kiyotaka
Kondo, Junichi Seino, Yuki Ohkawa, Tadashi Suzuki, Hiromasa Inoue, Takuro Kanekura, Naoshi
Dohmae, Naoyuki Taniguchi, Ikuro Maruyama. Glycometabolic Regulation of the Biogenesis ofSmall Extracellular Vesicles. Cell Rep. 2020 oct 13; 33(2): 108261.
3. Christopher E Brightling, Mina Gaga, Hiromasa Inoue, Jing Li, Jorge Maspero, SallyWenzel, Samopriyo Maitra, David Lawrence, Florian Brockhaus, Thomas Lehmann, Caterina
Brindicci, Barbara Knorr, Eugene R Bleecker. Effectiveness of fevipiprant in reducing exacerbations
in patients with severe asthma (LUSTER-1 and LUSTER-2): two phase 3 randomised controlled
trials. Lancet Respir Med. 2021 jan; 9(1): 43-56.
4. Saori Sakaue, Etsuro Yamaguchi, Yoshikazu Inoue, Meiko Takahashi, Jun Hirata, KenSuzuki, Satoru Ito, Toru Arai, Masaki Hirose, Yoshinori Tanino, Takefumi Nikaido, Toshio
Ichiwata, Shinya Ohkouchi, Taizou Hirano, Toshinori Takada, Satoru Miyawaki, Shogo
Dofuku, Yuichi Maeda, Takuro Nii, Toshihiro Kishikawa, Kotaro Ogawa, Tatsuo Masuda, Kenichi
Yamamoto, Kyuto Sonehara, Ryushi Tazawa, Konosuke Morimoto, Masahiro Takaki, Satoshi
Konno, Masaru Suzuki, Keisuke Tomii, Atsushi Nakagawa, Tomohiro Handa, Kiminobu
Tanizawa, Haruyuki Ishii, Manabu Ishida, Toshiyuki Kato, Naoya Takeda, Koshi
Yokomura, Takashi Matsui, Masaki Watanabe, Hiromasa Inoue, Kazuyoshi Imaizumi, Yasuhiro
Goto, Hiroshi Kida, Tomoyuki Fujisawa, Takafumi Suda, Takashi Yamada, Yasuomi
Satake, Hidenori Ibata, Nobuyuki Hizawa, Hideki Mochizuki, Atsushi Kumanogoh, FumihikoMatsuda, Koh Nakata, Tomomitsu Hirota, Mayumi Tamari, Yukinori Okada. Genetic determinantsof risk in autoimmune pulmonary alveolar proteinosis. Nat Commun. 2021 Feb 15; 12(1): 1032.
5. Shunsuke Misono, Keiko Mizuno, Takayuki Suetsugu, Kengo Tanigawa, Nijiro Nohata, Akifumi
Uchida, Hiroki Sanada, Reona Okada, Shogo Moriya, Hiromasa Inoue, Naohiko Seki. MolecularSignature of Small Cell Lung Cancer after Treatment Failure: The MCM Complex as Therapeutic
Target. Cancers (Basel). 2021 Mar 10; 13(6): 1187.
6. Hiromasa Inoue, Ki Lee Milligan, Aine McConnon, Hajime Yoshisue, Emil Loefroth, Martin

McSharry, Akihito Yokoyama, Masakazu Ichinose. Uncontrolled asthma: a retrospective cohort
study in Japanese patients newly prescribed with medium-/high-dose ICS/LABA. NPJ Prim CareRespir Med. 2021 Mar 2; 31(1): 12.
7. Takahiro Matsuyama, Kentaro Machida, Yasutaka Motomura, Koichi Takagi, Yoichi
Doutake, Asako Tanoue-Hamu, Kiyotaka Kondo, Keiko Mizuno, Kazuyo Moro, Hiromasa Inoue.
Long-acting muscarinic antagonist regulates group 2 innate lymphoid cell-dependent airway
eosinophilic inflammation. Allergy. 2021 Mar 31; 76(9): 2785-2796.
8. Toru Takeshita, Koichiro Matsumoto, Michiko Furuta, Satoru Fukuyama, KenjiTakeuchi, Hiroaki Ogata, Mikari Asakawa, Shinya Kageyama, Jun Hata, Toshiharu
Ninomiya, Hiromasa Inoue, Yoshihisa Yamashita. Airflow limitation and tongue microbiota incommunity-dwelling elderly individuals. ERJ Open Res. 2021 May 24; 7(2): 00616-2020.
9. Takayuki Takahashi, Hideyuki Terazono, Takayuki Suetsugu, Hideki Sugawara, Junko Arima,Mina Nitta, Toru Tanabe, Kayu Okutsu, Ryuji Ikeda, Keiko Mizuno, Hiromasa Inoue, Yasuo Takeda.
High-Trough Plasma Concentration of Afatinib Is Associated with Dose Reduction. Cancers.(basel)
2021 Jul 8; 13(14): 3425.
10. Alvar Agusti, Neil Barnes, Alvaro A Cruz, Peter G Gibson, Liam G Heaney, Hiromasa
Inoue, David Leather, Fernando J Martinez, Vanessa M McDonald, John Oppenheimer, Alberto
Papi, Ian D Pavord, Mike Thomas, Samantha Walker, Louisa Yates. Moving towards a Treatable
Traits model of care for the management of obstructive airways diseases. Respir Med. 2021 Aug 13;
187: 106572.
総説
堂嶽洋一, 町田健太朗, 井上博雅: 好酸球性多発血管炎性肉芽腫症. (6.アレルギー性肺疾患)

呼吸器疾患診療指針 2021-’22. 2020.11.30; 215-221.
1. 東元一晃: 呼吸器内科領域のトピックス～膠原病性間質性肺疾患 肺がん COVID-19～.

鹿児島県内科医会報. 2021.1.1; 52: 14-15.
2. 安田俊介, 隈元朋洋, 内田章文, 井上博雅: 5 喘息.(第 5 章病態に応じた周術期での注意点).

月刊薬事.(臨時増刊号). 2021.2; 63(3): 199(533)-204(536).
3. 髙木弘一, 井上博雅: 2. 重症喘息発作 (Ⅲ.呼吸器系の救急治療).

呼吸器疾患最新の治療. 2021-2022. 2021.3.1 ; 143-146．

4. 町田健太朗: 【自然リンパ球と制御性 T 細胞の新知見】好酸球性喘息における 2 型自然リンパ球のTL1A/DR3 を介した活性化. 臨床免疫・アレルギー科. 2021.3; 75(3): 245-252.
5. 松山崇弘: 吸入手技習得における吸入デバイス説明媒体の有用性に関する検討.

鹿児島県医師会報. 2021.3; 令和 3 年 3 月号: 62-65.
6. 井上博雅: 気管支喘息. (よくわかる呼吸器疾患シリーズ). 国保かごしま. 2021.5; 624(5): 8-10.
7. 町田健太朗: 慢性閉塞性肺疾患(COPD).(よくわかる呼吸器疾患シリーズ).

国保かごしま. 2021.7; 625(7): 8-10.
8. 井上博雅: 気管支喘息(成人 ). (私の治療). 週刊日本医事新報. 2021.8.21; 5078: 36-38.
9. 水野圭子: 肺がん. (よくわかる呼吸器疾患シリーズ) 国保かごしま. 2021.9; 626(9): 8-10.
10. 町田健太朗, 井上博雅: 気管支喘息.(特集(Clinical Science/アレルギー疾患治療における分子標的薬の新展開)). 炎症と免疫. 2021.9; 29(5): 22(402-29(409).
著書
1. 町田健太朗, 井上博雅： Ⅳ アレルギー疾患 喘息，気道疾患 成人気管支喘息.

"別冊日本臨牀 領域別症候群シリーズ No.18 呼吸器症候群(第 3 版)Ⅱ". 2021.9; 42-48.
症例
1. 窪田幸司, 水野圭子, 八木朋子, 福田宏正, 武田亜矢, 井上博雅:
肺実質への進展が確認された気管支内腔型肺過誤腫の一例. 気管支学. 2020 Nov.; 42(6): 524-528.
その他
1. (letter) Mari Kirishima, Ikuma Kato, Masanori Hisaoka, Yukio Nakatani, Aya Harada Takeda,
Keiko Mizuno, Akihide Tanimoto: Solid endobronchial tumor with EWSR1‐FLI1 fusion gene –A
diagnostically challenging case of the Ewing sarcoma. Pathology International. 2021 June 10; 71(7):488-490.
2.(インタビュー)井上博雅, 水野圭子, 末次隆行: 鹿児島大学における肺癌診療と地域医療連携.

Frontiers in Lung Cancer. (中外製薬/ウェブインタビュー雑誌) 2021.1.19(インタビュー日時); 1-3.